Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

Craig Kovitz, Hagop Kantarjian, Guillermo Garcia-Manero, Lynne V. Abruzzo, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Philadelphia chromosome (Ph)-negative cells. These abnormalities are frequently transient and their clinical consequence is unclear. Although some reports have suggested that the abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has not always been established using standard criteria.We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells. One of them developed acute myelogenous leukemia (AML) and the other 2 developed high-risk MDS that rapidly transformed to AML. These cases were identified in a total study group of 1701 patients. Although these occurrences are rare, the findings highlight the need for close monitoring of patients with CML treated with imatinib.

Original languageEnglish (US)
Pages (from-to)2811-2813
Number of pages3
JournalBlood
Volume108
Issue number8
DOIs
StatePublished - Oct 15 2006
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia
Acute Myeloid Leukemia
Chromosome Aberrations
Philadelphia Chromosome
Physiologic Monitoring
Chromosomes
Therapeutics
Monitoring
Imatinib Mesylate

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. / Kovitz, Craig; Kantarjian, Hagop; Garcia-Manero, Guillermo; Abruzzo, Lynne V.; Cortes, Jorge.

In: Blood, Vol. 108, No. 8, 15.10.2006, p. 2811-2813.

Research output: Contribution to journalArticle

Kovitz, Craig ; Kantarjian, Hagop ; Garcia-Manero, Guillermo ; Abruzzo, Lynne V. ; Cortes, Jorge. / Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. In: Blood. 2006 ; Vol. 108, No. 8. pp. 2811-2813.
@article{edd77cfd3a424faabc1447a62f131f70,
title = "Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia",
abstract = "During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Philadelphia chromosome (Ph)-negative cells. These abnormalities are frequently transient and their clinical consequence is unclear. Although some reports have suggested that the abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has not always been established using standard criteria.We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells. One of them developed acute myelogenous leukemia (AML) and the other 2 developed high-risk MDS that rapidly transformed to AML. These cases were identified in a total study group of 1701 patients. Although these occurrences are rare, the findings highlight the need for close monitoring of patients with CML treated with imatinib.",
author = "Craig Kovitz and Hagop Kantarjian and Guillermo Garcia-Manero and Abruzzo, {Lynne V.} and Jorge Cortes",
year = "2006",
month = "10",
day = "15",
doi = "10.1182/blood-2006-04-017400",
language = "English (US)",
volume = "108",
pages = "2811--2813",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

AU - Kovitz, Craig

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

AU - Abruzzo, Lynne V.

AU - Cortes, Jorge

PY - 2006/10/15

Y1 - 2006/10/15

N2 - During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Philadelphia chromosome (Ph)-negative cells. These abnormalities are frequently transient and their clinical consequence is unclear. Although some reports have suggested that the abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has not always been established using standard criteria.We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells. One of them developed acute myelogenous leukemia (AML) and the other 2 developed high-risk MDS that rapidly transformed to AML. These cases were identified in a total study group of 1701 patients. Although these occurrences are rare, the findings highlight the need for close monitoring of patients with CML treated with imatinib.

AB - During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Philadelphia chromosome (Ph)-negative cells. These abnormalities are frequently transient and their clinical consequence is unclear. Although some reports have suggested that the abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has not always been established using standard criteria.We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells. One of them developed acute myelogenous leukemia (AML) and the other 2 developed high-risk MDS that rapidly transformed to AML. These cases were identified in a total study group of 1701 patients. Although these occurrences are rare, the findings highlight the need for close monitoring of patients with CML treated with imatinib.

UR - http://www.scopus.com/inward/record.url?scp=33750615550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750615550&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-04-017400

DO - 10.1182/blood-2006-04-017400

M3 - Article

C2 - 16809614

AN - SCOPUS:33750615550

VL - 108

SP - 2811

EP - 2813

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -